Neutrophils, as "Trojan horses", participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect

Drug Deliv. 2020 Dec;27(1):1-14. doi: 10.1080/10717544.2019.1701141.

Abstract

Inspired by the fact that leukocytes have innate phagocytic functions and oriented migration capabilities in response to chemoattractants, we have unveiled that endogenous neutrophils as "Trojan horses", participate in the delivery of nanoparticles in an "in vivo self-armed assembly" manner. Neutrophils were the main population to preferentially sequester the intravenous administrated nanoparticles with an average size of 260 nm. The pre-implantation of CXCL1-laden hydrogels could trigger and induce a targeted signal to attract an influx of neutrophils carrying the therapeutic goods to the desired position. In mouse models of melanoma, the combinatorial regimen of using the PLGA nanoparticles with the CXCL1 hydrogels exhibited superior tumor inhibition capability. This work leveraged the natural phagocytosis of neutrophile and the chemotactic effect of chemokines for targeted delivery. We believe this strategy will improve the therapeutic efficiency of nanoparticle-based delivery systems, especially when the chemokines are implanted at sites of surgical tumor removal, during cancer treatment at the clinic.

Keywords: Neutrophils; PLGA nanoparticles; Trojan horse; chemokines; paclitaxel.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Chemokine CXCL1 / pharmacology*
  • Drug Carriers / pharmacology*
  • Drug Liberation
  • Hydrogels
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / chemistry*
  • Neutrophils / metabolism*
  • Particle Size
  • Phagocytosis
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemistry*

Substances

  • Chemokine CXCL1
  • Drug Carriers
  • Hydrogels
  • Polylactic Acid-Polyglycolic Acid Copolymer

Grants and funding

This work was supported by grants obtained from National Basic Research Program of China [No. 2015CB943203], National Nature Science Foundation of China [No. 81102820, 81272315, 81172882], and Natural Science Foundation of Shandong Province [No. ZR2016HM21, ZR2017BC030], Scientific development program of Traditional Chinese Medicine of Shandong Province [2017-240], The Open Project of Shandong Collaborative Innovation Center for Antibody Drugs [No. CIC-AD1813].